Drugs / Rituximab-Pfizer
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01643928 | Aug 2012 → Mar 2016 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-12-02 | Pfizer | Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting pfizer.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rituximab-Pfizer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01643928 ↗ |
| Known as | PF-05280586 | “Rituximab-Pfizer (PF-05280586) x 3 courses” NCT01643928 ↗ |
| Route | Intravenous | “1000 mg intravenous infusion” NCT01643928 ↗ |